Caladrius Biosciences Reports Publication of Two-Year Results from Phase 1 Trial of Type 1 Diabetes Candidate

By: via Benzinga
Caladrius Biosciences, Inc. ("Caladrius" or the "Company") (NASDAQ: CLBS), a cell therapy company combining an industry-leading external ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.